
-
Enlivex Therapeutics NasdaqCM:ENLV Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Location: 14 Einstein Street, Ness Ziona, 7403618, Israel | Website: https://www.enlivex.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-786.8K
Cash
23.5M
Avg Qtr Burn
-3.252M
Short % of Float
0.58%
Insider Ownership
4.61%
Institutional Own.
13.43%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Allocetra (Immunotherapy) Details Treatment of organ failure associated with Sepsis, Organ failure | Phase 2b Update | |
Allocetra (Immunotherapy) Details Knee osteoarthritis | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) Details Osteoarthritis, Basal thumb osteoarthritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) Details TMJ Osteoarthritis | Phase 1 Data readout | |
Allocetra (Immunotherapy) + Chemotherapy Details Solid tumor/s, Cancer | Failed Discontinued | |
Allocetra (Immunotherapy) +/_ anti-PD1 checkpoint inhibitors Details Solid tumor/s, Cancer | Failed Discontinued | |
Tovinontrine (IMR-687) Details Beta thalessemia, Genetic disorder | Failed Discontinued | |
Tovinontrine (IMR-687) Details Sickle cell disease, Genetic disorder, Blood disorder | Failed Discontinued | |
Allocetra (Immunotherapy) Details COVID-19, Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued | |
Allocetra (Immunotherapy) Details Bone marrow transplantation, Prevention of post-bone marrow transplantations complications | Failed Discontinued |